| Williams, Patrick |
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) |
|
|
| Recruiting | 3 | 630 | US | ANX007, Sham Administration | Annexon, Inc. | Geographic Atrophy | 10/26 | 10/27 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). |
|
|
| Recruiting | 2 | 246 | US | Active Comparator CT1812, Placebo Comparator | Cognition Therapeutics | Age-Related Macular Degeneration | 07/27 | 08/27 | | |
| Recruiting | N/A | 3000 | US | Treatment Recommendation Surveys, 7-gene biosignature | PreludeDx, University of South Florida | DCIS | 12/25 | 12/35 | | |
| Hastings, Lori |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Wickremasinghe, Sanjeewa |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
NANO-C, NCT05570591: Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy |
|
|
| Recruiting | N/A | 60 | RoW | 2RT subthreshold nanosecond laser - active, 2RT, SNL, 2RT subthreshold nanosecond laser - sham, Sham laser | Nova Eye Medical Pty Ltd., Centre for Eye Research Australia | Central Serous Chorioretinopathy | 12/24 | 12/24 | | |
| Crawford, Courtney |
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). |
|
|
| Recruiting | 2 | 246 | US | Active Comparator CT1812, Placebo Comparator | Cognition Therapeutics | Age-Related Macular Degeneration | 07/27 | 08/27 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Renfroe, Cori |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Taing, Rebecca |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Shah, Girag |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Berdia, Jay |
GION, NCT06178055: A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) |
|
|
| Active, not recruiting | 2 | 75 | US | KUS121 high dose, KUS121 low dose, Sham procedure | Kyoto Drug Discovery and Development Co., Ltd. | Central Retinal Artery Occlusion | 03/25 | 12/25 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Yagi, Fumihiko |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Takahas, Hidenori |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Hagiwara, Akira |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
| Suan, Eric |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
| McMahon, Charles |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
| Larsen, Cynthia |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
